Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients with inadequate efficacy response to prior therapy: 4-year follow-up of CARE-MS II

被引：0
|
作者：
Arroyo Gonzalez, R. [1 ]
Moreau, T. [2 ]
Cohen, J. A. [3 ]
Giovannoni, G. [4 ]
Margolin, D. H. [5 ]
Kasten, L. [6 ]
Havrdova, E. [7 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Burgundy Univ, Dijon Univ Hosp, Dijon, France
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Queen Mary Univ London, Barts & London Sch Med, London, England
[5] Genzyme, Cambridge, MA USA
[6] PROMETRIKA LLC, Cambridge, MA USA
[7] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2015年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
F2070
引用
收藏
页码：614 / 614
页数：1
相关论文
共 50 条
  • [31] Alemtuzumab Suppresses MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy: CARE-MS II
    Schippling, Sven
    Traboulsee, Anthony
    Barnett, Michael
    Comi, Giancarlo
    De Seze, Jerome
    Giovannoni, Gavin
    Pelletier, Daniel
    Rovira, Alex
    Margolin, David H.
    Thangavelu, Karthinathan
    Arnold, Douglas L.
    NEUROLOGY, 2017, 88
  • [32] Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy
    Cohen, Jeffrey
    Twyman, Cary
    Arnold, Douglas
    Coles, Alasdair
    Confavreux, Christian
    Fox, Edward
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Miller, Tamara
    Lake, Stephen
    Margolin, David
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2012, 78
  • [33] Quality of life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II
    Vermersch, P.
    Giovannoni, G.
    Cohen, J. A.
    Moreau, T.
    Wray, S.
    Margolin, D. H.
    Kasten, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 621 - 621
  • [34] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
    Wiendl, H.
    Palmer, J.
    Margolin, D. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 683 - 683
  • [35] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
    Wiendl, H.
    Palmer, J.
    Margolin, D. H.
    JOURNAL OF NEUROLOGY, 2014, 261 : S442 - S443
  • [36] Durable effect of alemtuzumab on MRI lesion outcomes over 5 years in patients with highly active relapsing-remitting multiple sclerosis who had an inadequate response to prior therapy (CARE-MS II)
    Comi, G.
    Berkovich, R.
    Rovira, A.
    Pelletier, D.
    Schippling, S.
    Traboulsee, A.
    Vermersch, P.
    Margolin, D. H.
    Thangavelu, K.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 283 - 284
  • [37] Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up
    Oreja-Guevara, Celia
    Alroughani, Raed
    Brassat, David
    Boyko, Alexey N.
    McCombe, Pamela
    Steingo, Brian
    Van Wijmeersch, Bart
    Margolin, David H.
    Thangavelu, Karthinathan
    Rodriguez, Claudio E.
    Vermersch, Patrick
    NEUROLOGY, 2017, 88
  • [38] Lymphocyte counts and infection risk among relapsing-remitting multiple sclerosis patients treated with alemtuzumab (CARE-MS II)
    Havrdova, E.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Selmaj, K. W.
    Weiner, H. L.
    Miller, T.
    Twyman, C. L.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M. A.
    Compston, D. A. S.
    JOURNAL OF NEUROLOGY, 2013, 260 : S120 - S120
  • [39] Alemtuzumab Improves Patient-reported Quality of Life Outcomes in Patients With Relapsing-remitting Multiple Sclerosis: Results From the CARE-MS I Extension Study
    Arroyo, Rafael
    Guo, Jennifer D.
    Zhang, Wei
    Thangavelu, Karthinathan
    Chung, Luke
    Moon, Jungyoon
    Keith, Michael
    Cella, David
    NEUROLOGY, 2018, 90
  • [40] Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)
    Oreja-Guevara, C.
    Alroughani, R.
    Brassat, D.
    Boyko, A. N.
    McCombe, P.
    Steingo, B.
    Van Wijmeersch, B.
    Margolin, D. H.
    Thangavelu, K.
    Rodriguez, C. E.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 648 - 649
12345